Eosinophilic Gastroenteritis: Clinical Manifestation, Natural Course, and Evaluation of Treatment with Corticosteroids and Vedolizumab

  • Tanja Grandinetti
  • Luc Biedermann
  • Christian Bussmann
  • Alex Straumann
  • Petr HruzEmail author
Original Article



Eosinophilic gastroenteritis (EGE) is a rare, chronic inflammatory condition of the gastrointestinal tract. Little is known about its natural history and treatment outcomes. The aims of our analysis were to describe clinical presentation, response to current medical treatments, and to evaluate the response of refractory EGE to anti-integrin therapy.


Patients with confirmed diagnosis of EGE fulfilling the diagnostic criteria: (1) the presence of gastrointestinal symptoms, (2) dense eosinophilic infiltration of the gastrointestinal mucosa, and (3) exclusion of other conditions leading to gastrointestinal eosinophilia were included in this analysis. In patients non-responding to corticosteroids and/or anti-TNF treatment the integrin blocker vedolizumab was used.


EGE patients (n = 22) were predominantly female (63%) with a median age at diagnosis of 41.5 years. The most frequent symptoms were abdominal pain (100%), diarrhea (59%), nausea/vomiting (36%), and bloating (27%). No pathognomonic endoscopic alterations were found. Eosinophilic infiltration was observed in the majority of patients in more than one segment. Patients were treated with systemic steroids, topical, and enteral release steroids in 21/22 (95%) patients, proton pump inhibitors in 7/22 (32%), TNFα inhibitors in 3/22 (14%), and vedolizumab in 4/22 (18%) patients. In 3/4 of steroid-refractory patients vedolizumab induced a clinical and histological improvement.


The combination of highly variable clinical presentation, subtle endoscopic abnormalities, and involvement of several GI segments undermines the difficulty to diagnose EGE and the need for structured biopsy sampling. Corticosteroids were efficient in the majority of patients to induce remission. Response to the integrin blocker vedolizumab suggests further assessment in refractory cases.


Eosinophilic gastroenteritis Vedolizumab Steroid-refractory 



Eosinophilic esophagitis


Eosinophilic gastroenteritis


Eosinophilic gastrointestinal diseases


High power field


Immunoglobulin E


Patient global assessment


Proton pump inhibitor


Tumor necrosis factor alpha


Author’s contribution

PH and AS conceptualized and designed the clinical question and drafted the initial manuscript; TG and LB evaluated the patient data and drafted the initial manuscript; CB performed histological analysis and critically reviewed the manuscript. All authors read and approved the final manuscript as submitted.

Compliance with ethical standards

Conflict of interest

The authors have no conflicts of interest to disclose.

Supplementary material

10620_2019_5617_MOESM1_ESM.docx (26 kb)
Supplementary material 1 (DOCX 25 kb)


  1. 1.
    Klein NC, Hargrove RL, Sleisenger MH, et al. Eosinophilic gastroenteritis. Medicine (Baltimore). 1970;49:299–319.CrossRefGoogle Scholar
  2. 2.
    Zur Kenntnis der allergischen RK. Affektionen des Verdaungskanal von Standpunkt des Chirurgen aus. Arch Klin Chir. 1937;188.Google Scholar
  3. 3.
    Yan BM, Shaffer EA. Primary eosinophilic disorders of the gastrointestinal tract. Gut. 2009;58:721–732.CrossRefGoogle Scholar
  4. 4.
    Mansoor E, Saleh MA, Cooper GS. Prevalence of eosinophilic gastroenteritis and colitis in a population-based study, from 2012 to 2017. Clin Gastroenterol Hepatol. 2017;15:1733–1741.CrossRefGoogle Scholar
  5. 5.
    Reed C, Woosley JT, Dellon ES. Clinical characteristics, treatment outcomes, and resource utilization in children and adults with eosinophilic gastroenteritis. Dig Liver Dis. 2015;47:197–201.CrossRefGoogle Scholar
  6. 6.
    Walker MM, Potter M, Talley NJ. Eosinophilic gastroenteritis and other eosinophilic gut diseases distal to the oesophagus. Lancet Gastroenterol Hepatol. 2018;3:271–280.CrossRefGoogle Scholar
  7. 7.
    DeBrosse CW, Case JW, Putnam PE, et al. Quantity and distribution of eosinophils in the gastrointestinal tract of children. Pediatr Dev Pathol. 2006;9:210–218.CrossRefGoogle Scholar
  8. 8.
    Lwin T, Melton SD, Genta RM. Eosinophilic gastritis: histopathological characterization and quantification of the normal gastric eosinophil content. Mod Pathol. 2011;24:556–563.CrossRefGoogle Scholar
  9. 9.
    Matsushita T, Maruyama R, Ishikawa N, et al. The number and distribution of eosinophils in the adult human gastrointestinal tract: a study and comparison of racial and environmental factors. Am J Surg Pathol. 2015;39:521–527.CrossRefGoogle Scholar
  10. 10.
    Pineton de Chambrun G, Gonzalez F, Canva JY, et al. Natural history of eosinophilic gastroenteritis. Clin Gastroenterol Hepatol. 2011;9:950–956.CrossRefGoogle Scholar
  11. 11.
    Kinoshita Y, Furuta K, Ishimaura N, et al. Clinical characteristics of Japanese patients with eosinophilic esophagitis and eosinophilic gastroenteritis. J Gastroenterol. 2013;48:333–339.CrossRefGoogle Scholar
  12. 12.
    Ko HM, Morotti RA, Yershov O, et al. Eosinophilic gastritis in children: clinicopathological correlation, disease course, and response to therapy. Am J Gastroenterol. 2014;109:1277–1285.CrossRefGoogle Scholar
  13. 13.
    Bischoff SC, Mayer J, Nguyen QT, et al. Immunnohistological assessment of intestinal eosinophil activation in patients with eosinophilic gastroenteritis and inflammatory bowel disease. Am J Gastroenterol. 1999;94:3521–3529.CrossRefGoogle Scholar
  14. 14.
    Kephart GM, Alexander JA, Arora AS, et al. Marked deposition of eosinophil-derived neurotoxin in adult patients with eosinophilic esophagitis. Am J Gastroenterol. 2010;105:298–307.CrossRefGoogle Scholar
  15. 15.
    Torpier G, Colombel JF, Mathieu-Chandelier C, et al. Eosinophilic gastroenteritis: ultrastructural evidence for a selective release of eosinophil major basic protein. Clin Exp Immunol. 1988;74:404–408.Google Scholar
  16. 16.
    Zhang L, Duan L, Ding S, et al. Eosinophilic gastroenteritis: clinical manifestations and morphological characteristics, a retrospective study of 42 patients. Scand J Gastroenterol. 2011;46:1074–1080.CrossRefGoogle Scholar
  17. 17.
    Attar A, Cazals-Hatem D, Ponsot P. Videocapsule endoscopy identifies stenoses missed by other imaging techniques in a patient with eosinophilic gastroenteritis. Clin Gastroenterol Hepatol. 2011;9:A28.CrossRefGoogle Scholar
  18. 18.
    Pasha SF, Leighton JA, Williams JW, et al. Capsule retention in a patient with eosinophilic gastroenteritis mimicking diaphragm disease of the small bowel. Endoscopy. 2009;41:E290–E291.CrossRefGoogle Scholar
  19. 19.
    Talley NJ, Walker MM, Aro P, et al. Non-ulcer dyspepsia and duodenal eosinophilia: an adult endoscopic population-based case-control study. Clin Gastroenterol Hepatol. 2007;5:1175–1183.CrossRefGoogle Scholar
  20. 20.
    Egan M, Furuta GT. Eosinophilic gastrointestinal diseases beyond eosinophilic esophagitis. Ann Allergy Asthma Immunol. 2018;121:162–167.CrossRefGoogle Scholar
  21. 21.
    Collins MH, Capocelli K, Yang GY. Eosinophilic gastrointestinal disorders pathology. Front Med (Lausanne). 2017;4:261.CrossRefGoogle Scholar
  22. 22.
    Greuter T, Bussmann C, Safroneeva E, et al. Long-term treatment of eosinophilic esophagitis with swallowed topical corticosteroids: development and evaluation of a therapeutic concept. Am J Gastroenterol. 2017;112:1527–1535.CrossRefGoogle Scholar
  23. 23.
    Muir A, Surrey L, Kriegermeier A, et al. Severe eosinophilic gastroenteritis in a Crohn’s disease patient treated with infliximab and adalimumab. Am J Gastroenterol. 2016;111:437–438.CrossRefGoogle Scholar
  24. 24.
    Redondo-Cerezo E, Cabello MJ, Gonzalez Y, et al. Eosinophilic gastroenteritis: our recent experience: one-year experience of atypical onset of an uncommon disease. Scand J Gastroenterol. 2001;36:1358–1360.CrossRefGoogle Scholar
  25. 25.
    Turner D, Wolters VM, Russell RK, et al. Anti-TNF, infliximab, and adalimumab can be effective in eosinophilic bowel disease. J Pediatr Gastroenterol Nutr. 2013;56:492–497.CrossRefGoogle Scholar
  26. 26.
    Amiot A, Grimaud JC, Peyrin-Biroulet L, et al. Effectiveness and safety of vedolizumab induction therapy for patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2016;14:e2.CrossRefGoogle Scholar
  27. 27.
    Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699–710.CrossRefGoogle Scholar
  28. 28.
    Loftus EV Jr, Colombel JF, Feagan BG, et al. Long-term efficacy of vedolizumab for ulcerative colitis. J Crohns Colitis. 2017;11:400–411.Google Scholar
  29. 29.
    Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369:711–721.CrossRefGoogle Scholar
  30. 30.
    Vermeire S, Loftus EV Jr, Colombel JF, et al. Long-term efficacy of vedolizumab for Crohn’s disease. J Crohns Colitis. 2017;11:412–424.Google Scholar
  31. 31.
    Rieder F, Biancani P, Harnett K, et al. Inflammatory mediators in gastroesophageal reflux disease: impact on esophageal motility, fibrosis, and carcinogenesis. Am J Physiol Gastrointest Liver Physiol. 2010;298:G571–G581.CrossRefGoogle Scholar
  32. 32.
    Kim HP, Reed CC, Herfarth HH, et al. Vedolizumab treatment may reduce steroid burden and improve histology in patients with eosinophilic gastroenteritis. Clin Gastroenterol Hepatol. 2018;16:1992–1994.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Gastroenterology and HepatologyUniversity Hospital BaselBaselSwitzerland
  2. 2.Division of Gastroenterology and HepatologyUniversity Hospital ZurichZurichSwitzerland
  3. 3.Swiss EoE Clinic, Division of GastroenterologyUniversity Hospital ZurichZurichSwitzerland
  4. 4.Institute of Pathology ViollierBaselSwitzerland

Personalised recommendations